"Provide a new potent brachytherapy tool for the treatment of cancers in
humans and animals that will be very effective in improving the lives of
The Company obtained clarification from the FDA Center for Veterinary Medicine that IsoPet® is classified as a device for skin cancer therapy in cats and dogs. The FDA also reviewed and
approved the product labeling. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market
sector. Vivos is positioning itself so that after this demonstration phase, The Company can begin to generate revenues through the sale of IsoPet® to University animal hospitals and private
veterinary clinic consortiums.
you can edit this section directly in HTML ( templates > custom template > html )
Vivos Inc to Present at The LD 500 Virtual Conference
LOS ANGELES, CA / ACCESSWIRE / September 1, 2020 / Vivos Inc (OTCQB:RDGL), a company that has developedan Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals and in humans, today announced that it will
be presenting at the LD 500 investor conference on Thursday September 3 at 1:40 PST / 4:00 PM EST. Dr. Mike Korenko (CEO of Vivos Inc) will be presenting to a live virtual
"We have been waiting for this moment all year long. Due to COVID, it has been nearly impossible for physical conferences to even take place. I want to show the world that you can still learn,
have a great time, and see some of the most unique companies in the capital markets today. All without having to step foot outside. For the first time, LD Micro is accessible to everyone, and we
are honored to welcome you to one of the most trusted platforms in the space." stated Chris Lahiji, Founder of LD.
The LD 500 will take place on September 1st through the 4th.